Bionoid Pharma Inc

Healthcare US BINP

NoneUSD
0.00(0%)

Last update at 2026-06-04T21:40:46.845097Z

Day Range

LowHigh

52 Week Range

0.010.15

LowHigh

Fundamentals

Previous Close -
Market Cap1.37M
VolumeNone
P/E Ratio-
Dividend Yield-%
EBITDA-0.38571M
Revenue TTM0.09M
Revenue Per Share TTM2.63
Gross Profit TTM 0.05M
Diluted EPS TTM-0.16

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Income before tax	-0.27800M	0.01M	0.00148M	-0.13500M	-0.45578M
Minority interest	-	-	-	-	-
Net income	-0.31700M	0.01M	0.00148M	-0.13500M	-0.45578M
Selling general administrative	-	-	-	-	-
Selling and marketing expenses	-	-	-	-	-
Gross profit	-0.27657M	0.00842M	0.02M	0.05M	0.01M
Reconciled depreciation	-	-	-	-	-
Ebit	0.28M	-0.00732M	0.00186M	-0.13500M	-0.03248M
Ebitda	0.55M	-0.00432M	0.00486M	-0.13200M	-0.02948M
Depreciation and amortization	0.28M	0.00300M	0.00300M	0.00300M	0.00300M
Non operating income net other	-	-	-	-	-
Operating income	-0.27657M	0.01M	0.00186M	-0.07983M	-0.03248M
Other operating expenses	0.28M	0.04M	0.03M	0.18M	0.06M
Interest expense	0.00165M	0.00177M	0.00038M	0.00039M	-
Tax provision	-	-	-	-	-
Interest income	-	-	-	-	-
Net interest income	-	-	-	-	-
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	-0.00781M	0.00000M	-0.00000M	-
Total revenue	-	0.04M	0.04M	0.10M	0.03M
Total operating expenses	-	0.02M	0.02M	0.13M	0.05M
Cost of revenue	0.28M	0.03M	0.02M	0.06M	0.02M
Total other income expense net	-0.00165M	-0.00177M	-0.00038M	-0.05543M	-0.42330M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-	-	-	-	-
Net income applicable to common shares	-	-	-	-	-
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total assets	-	0.07M	0.08M	0.08M	0.12M
Intangible assets	-	0.02M	0.02M	0.02M	-
Earning assets	-	-	-	-	-
Other current assets	-	0.05M	0.06M	-0.00522M	0.12M
Total liab	-	0.15M	0.16M	0.16M	0.16M
Total stockholder equity	-	-0.08403M	-0.07623M	-0.07771M	-0.04090M
Deferred long term liab	-	-	-	-	-
Other current liab	-	-0.00025M	-	0.00000M	-
Common stock	-	0.00540M	1.46M	1.46M	1.44M
Capital stock	-	-	-	-	-
Retained earnings	-	-19.17783M	-20.71353M	-20.71500M	-20.57974M
Other liab	-	-	-	-	-
Good will	-	-	-	-	-
Other assets	-	-	-	0.00000M	-
Cash	-	0.00269M	0.00246M	0.02M	0.00063M
Cash and equivalents	-	-	-	-	-
Total current liabilities	-	0.15M	0.16M	0.16M	0.16M
Current deferred revenue	-	-	-	-	-
Net debt	-	0.15M	0.15M	0.13M	0.16M
Short term debt	-	0.15M	0.15M	0.15M	0.16M
Short long term debt	-	-	-	-	-
Short long term debt total	-	0.15M	0.15M	0.15M	0.16M
Other stockholder equity	-	19.09M	-1.46403M	-1.45848M	-1.44352M
Property plant equipment	-	-	-	-	-
Total current assets	-	0.05M	0.06M	0.06M	0.12M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	-	-
Short term investments	-	-	-	-	-
Net receivables	-	-	-	0.04M	-
Long term debt	-	-	-	-	-
Inventory	-	-	-	-	-
Accounts payable	-	0.00025M	0.00450M	0.00710M	-
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-	20.64M	20.64M	20.54M
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-	-0.03951M	-	-0.00000M	-
Deferred long term asset charges	-	-	-	-	-
Non current assets total	-	0.02M	0.02M	0.02M	-
Capital lease obligations	-	-	-	-	-
Long term debt total	-	-	-	-	-

Breakdown	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Investments	-	-	-	-	-
Change to liabilities	-	-	-	-	-
Total cashflows from investing activities	-	-	0.02M	-	-
Net borrowings	-	-	-	-	-
Total cash from financing activities	-	-0.00005M	0.02M	0.05M	-0.11364M
Change to operating activities	-	-	-	-	-
Net income	-0.00781M	0.00148M	-0.08606M	-0.45578M	0.03M
Change in cash	0.00023M	-0.02070M	0.02M	0.00049M	0.00026M
Begin period cash flow	0.00246M	0.02M	0.00063M	0.00014M	-0.00012M
End period cash flow	0.00269M	0.00246M	0.02M	0.00063M	0.00014M
Total cash from operating activities	0.00023M	-0.02065M	-0.01926M	-0.04655M	0.07M
Issuance of capital stock	-	-	-	-	-
Depreciation	0.00300M	0.00300M	0.00300M	0.00300M	0.00300M
Other cashflows from investing activities	-	-	-	-	-
Dividends paid	-	-	-	-	-
Change to inventory	-	-	-0.04176M	-	-
Change to account receivables	-	-	0.04M	-	-
Sale purchase of stock	-	-	-	-	-0.16982M
Other cashflows from financing activities	-	-0.00005M	0.02M	-0.00295M	-0.11364M
Change to netincome	-	-	-	-	-
Capital expenditures	0.00000M	0.00001M	0.00000M	0.00000M	0.00000M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	0.00504M	-0.02512M	-0.03006M	-	-
Stock based compensation	-	-	-	-	-
Other non cash items	0.01M	0.00861M	0.09M	0.41M	0.04M
Free cash flow	0.00023M	-0.02065M	-0.01926M	-0.04655M	0.07M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to EBITDA (x)
BINP Bionoid Pharma Inc	- -%	-	-	-	14.88	-	-2.6754
ABT Abbott Laboratories	2.70 3.07%	90.53	25.97	17.24	3.57	3.20	3.81	16.75
SYK Stryker Corporation	5.31 1.74%	310.00	44.07	24.94	5.51	6.12	6.05	25.73
MDT Medtronic PLC	1.36 1.72%	80.63	26.60	15.87	3.35	2.08	3.90	14.12
BSX Boston Scientific Corp	1.27 2.86%	45.60	31.49	17.24	4.41	3.65	4.88	19.19

Reports Covered

View All

Profile

AI Maverick Intel, Inc., an AI company, focuses on acquiring and enhancing businesses through its proprietary AI Maverick platform. Its technology streamlines the customer acquisition process by automating two way communication and data-driven engagement with its clients ideal audience segments across healthcare, biotech, and other sectors. The company was formerly known as Bionoid Pharma Inc. and changed its name to AI Maverick Intel, Inc. in April 2025. AI Maverick Intel, Inc. was incorporated in 2006 and is based in Beverly Hills, California.

Bionoid Pharma Inc

433 North Camden, Beverly Hills, CA, United States, 90210

800 784 7641
https://aimaverickintel.com
Employees : 5

Key Executives

Name	Title	Year Born
Ms. Patricia Colvin	Director of Operations & Financial Controller	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.